Azacitidine for the treatment of relapsed and refractory AML in older patients-Reference-Cited by-同舟云学术

Azacitidine for the treatment of relapsed and refractory AML in older patients

Published:2015-02 Issue:2 Volume:39 Page:124-130
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Itzykson Raphael,Thépot Sylvain,Berthon Céline,Delaunay Jacques,Bouscary Didier,Cluzeau Thomas,Turlure Pascal,Prébet Thomas,Dartigeas Caroline,Marolleau Jean-Pierre,Recher Christian,Plantier Isabelle,Stamatoullas Aspasia,Devidas Alain,Taksin Anne-Laure,Guièze Romain,Caillot Denis,Vey Norbert,Adès Lionel,Ifrah Norbert,Dombret Hervé,Fenaux Pierre,Gardin Claude

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference29 articles.

1. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet;Dohner;Blood,2010

2. Outcome of older patients with acute myeloid leukemia in first relapse;Sarkozy;Am J Hematol,2013

3. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial;Faderl;J Clin Oncol,2012

4. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study;Fenaux;Lancet Oncol,2009

5. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia;Fenaux;J Clin Oncol,2010

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial;Clinical Lymphoma Myeloma and Leukemia;2024-06

2. Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody–drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study;The Lancet Oncology;2024-03

3. Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study;Annals of Hematology;2024-01-26

4. Azacitidine–venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients;European Journal of Haematology;2023-11-29

5. Treating acute myelogenous leukemia in patients aged 70 and above: Recommendations from the International Society of Geriatric Oncology (SIOG);Journal of Geriatric Oncology;2023-09